➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Boehringer Ingelheim
Mallinckrodt
Colorcon
Merck

Last Updated: June 6, 2020

DrugPatentWatch Database Preview

Ibritumomab tiuxetan - Biologic Drug Details


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for ibritumomab tiuxetan

Identify potential brand extensions & biosimilar entrants

SponsorPhase
National Cancer Institute (NCI)Phase 3
University of California, DavisPhase 2
Spectrum Pharmaceuticals, IncPhase 3

See all ibritumomab tiuxetan clinical trials

Recent Litigation for ibritumomab tiuxetan

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
GENENTECH, INC. v. CELLTRION, INC.2018-01-12
GENENTECH, INC. v. SANDOZ, INC.2017-12-21
Biogen Idec, Inc. v. Glaxosmithkline LLC2010-03-24

See all ibritumomab tiuxetan litigation

Company Disclosures: US Patents for ibritumomab tiuxetan

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial Idec Pharmaceuticals Corporation (San Diego, CA) 2015-04-07 RX Orphan company
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial IDEC Pharmaceuticals Corporation (San Diego, CA) 2015-07-07 RX Orphan company
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial 2015-12-01 RX Orphan company
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial IDEC Pharmaceuticals Corporation (San Diego, CA) 2039-03-29 RX Orphan company
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial IDEC Pharmaceutical Corporation (San Diego, CA) 2019-06-04 RX Orphan company
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial IDEC Pharmaceuticals Corporation (San Diego, CA) 2021-01-27 RX Orphan company
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial Biogen IDEC Inc. (Cambridge, MA) 2019-03-01 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for ibritumomab tiuxetan

These patents were identified by searching patent claims

Supplementary Protection Certificates for ibritumomab tiuxetan

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0669836/01 Switzerland   Start Trial FORMER OWNER: BIOGEN INC., US
2004000036 Germany   Start Trial FORMER OWNER: BIOGEN IDEC INC.(N.D.GES.D.STAATES DELAWARE), SAN DIEGO, CALIF., US
2016000070123 Italy   Start Trial PRODUCT NAME: RITUXIMAB IN ASSOCIAZIONE CON IALURONIDASI RICOMBINANTE UMANA - SOLUZIONE PER INIEZIONE SOTTOCUTANEA(MABTHERA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/98/067/001-003, 20140326
C/GB04/025 United Kingdom   Start Trial PRODUCT NAME: IBRITUMOMAB COMPRISING A CHELATING AGENT FOR YTTRIUM (90); REGISTERED: UK EU/1/03/264/001 20040116
2016 00031 Denmark   Start Trial PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326
2004901230024 Italy   Start Trial PRODUCT NAME: IBRITUMOMAB(ZEVALIN); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/03/264/001, 20040116
2000149/01 Switzerland   Start Trial PRODUCT NAME: RITUXIMABUM; REGISTRATION NO/DATE: IKS 54378 19971127
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Merck
Medtronic
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.